UK markets closed

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
8.68+0.62 (+7.76%)
At close: 05:32PM BST
Currency in GBp

Valuation measures4

Market cap (intra-day) 20.72M
Enterprise value 8.76M
Trailing P/E 53.33
Forward P/E 65.36
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.81
Price/book (mrq)0.50
Enterprise value/revenue 5.77
Enterprise value/EBITDA -0.50

Trading information

Stock price history

Beta (5Y monthly) 1.64
52-week change 3-82.22%
S&P500 52-week change 3-4.45%
52-week high 352.00
52-week low 35.52
50-day moving average 39.13
200-day moving average 323.10

Share statistics

Avg vol (3-month) 3898.84k
Avg vol (10-day) 31.69M
Shares outstanding 5257.39M
Implied shares outstanding 6N/A
Float 8137.89M
% held by insiders 146.12%
% held by institutions 19.28%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)31 Dec 2021


Profit margin 0.00%
Operating margin (ttm)-1,313.50%

Management effectiveness

Return on assets (ttm)-32.41%
Return on equity (ttm)-54.23%

Income statement

Revenue (ttm)1.52M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-29.30%
Gross profit (ttm)539k
EBITDA -18.33M
Net income avi to common (ttm)-19.34M
Diluted EPS (ttm)-8.70
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.12M
Total cash per share (mrq)0.06
Total debt (mrq)156k
Total debt/equity (mrq)0.38
Current ratio (mrq)5.11
Book value per share (mrq)0.19

Cash flow statement

Operating cash flow (ttm)-16.74M
Levered free cash flow (ttm)-13.19M